Phase 1 N=48 Cardiac Safety Evaluation of P03277
Healthy Volunteers
Primary: Change-from-baseline Mean Effect of P03277 on QT Interval Expressed as QTc According to Fridericia's Formula (∆QTcF) — 0.97; 5.05; 0.24; -0.11 milliseconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=48 Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT)
Anesthesia; Adverse Effect · Cardiac Arrhythmia
Primary: Change-from-baseline in QTc Interval — 2.1; 5.1; -0.1; 4.1 ms — p=<0.05
Phase 1 N=47 This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)
Healthy
Primary: Change From Baseline in QTcF at That Timepoint Between 20 Minutes to 24 Hours After Drug Administration Where the Difference of Means in QTcF Changes From Baseline…
Phase 4 N=50 Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Prolonged QTc Interval
Primary: Maximum Difference in Change From Baseline in ddQTcF Following a Single Dose of 33 mg/kg Deferiprone — 1.4; -1.6 milliseconds
Phase 1 N=44 A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects
Healthy
Primary: Time-Matched Mean Difference in Corrected QT Interval Using Fridericia's Correction Method (QTcF) for PF-04447943 and Placebo at 0.5 Hour Post-Dose — 404.09; 408.92…
Phase 1 N=22 Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects
Drug-induced Surface ECG Changes
Primary: Placebo, and Baseline-adjusted Changes in PR, QRS, J-Tpeak, Tpeak-Tend and QTc — 6.5; 2.3; 32.1; 5.1 ms — p=<0.05
Phase 1 N=112 A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
Autoimmune Diseases
Primary: Change-from-baseline QT Interval Corrected for Heart Rate Using Fridericia's Method (QTcF) — 1.5; 0.9 msec
Phase 1 N=38 Concentration-QT Study of Paroxetine in Healthy Adults
Anxiety Disorders
Primary: Change From Baseline in Corrected QT Interval by Fridericia (QTcF Interval) — 1.9; 1.0; 0.9; 2.2 Milliseconds
Phase 1 N=94 A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
Healthy Subjects
Primary: Comparison of Least Squares (LS) Mean Changes From Baseline in Population-based Corrected QT Intervals (QTcP) Between Exenatide and Placebo on Day 1 Averaged Over 1300h…
Phase 1 N=40 Thorough QT Study of Intravenous Amisulpride
Healthy
Primary: Maximal Mean ΔΔQTcF — 5.0; 23.4; 0.8; 12.3 milliseconds
Phase 1 N=48 Staccato Prochlorperazine Thorough QT/QTc
Cardiotoxicity
Primary: Maximum Effect of Inhaled Prochlorperazine on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.493; 5.229 milliseconds
Phase 1 N=83 Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
Healthy Volunteers
Primary: Change From Baseline in Electrocardiogram Results (QTcNi) at Time of Maximum Plasma Concentration (Tmax) on Day 1 — -3.37; 12.96; -0.94; -0.91 msec
Phase 1 N=38 Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects
Healthy Subjects
Primary: QTc Effect of Single Subcutaneous (SC) Injections of Motixafortide (BL-8040) 1.25 mg/kg and 2 mg/kg — -0.6; 1.1; -3.0; -1.1 ms
Phase 1 N=60 Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers
QT Effects in Healthy Volunteers
Primary: Mean Change From Baseline in QTc Interval (Corrected by Friderica's Formula, dQTcF) Associated With Plasma Moxidectin Concentrations After a Single Dose — -5.1; -4.5…
Phase 4 N=60 ADASUVE 2-dose Thorough QT/QTc Study
Healthy Volunteers
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 4.04 msec
N/A N=35 Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Phase 1 N=70 Study to Assess the Effect of Omecamtiv Mecarbil (OM) on QT/QTc Intervals in Healthy Adults
QT Intervals Changes · QTc Intervals Changes
Primary: Placebo-corrected Change From Baseline in QT Interval Corrected for Heart Rate Based on the Fridericia Method (QTcF) After Omecamtiv Mecarbil Dosing in Part B — -2.6…
Phase 1 N=31 Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval
Duchenne and Becker Muscular Dystrophy · Polycytemia Vera
Primary: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval (QTcF) — 1.0; 0.5; 10.2; 0.3 Milliseconds (msec)
Phase 1 N=60 Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
Healthy
Primary: Mean Difference Changes From Baseline Versus Placebo in QTcNi Intervals From Time-Matched Analysis by Largest Time Point — 7.0; 13.0; 12.6 msec — p=<0.001
Phase 1 N=30 Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects
Healthy
Primary: Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing — 3.68; 4.27 ms
Phase 1 N=57 Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects
Healthy Volunteers
Primary: Change-From-Baseline QTcF at Dose Level B Measured on 12-Lead ECGs Extracted From Continuous Recordings — -0.1; -0.6; -0.1; 0.1 ms
Phase 1 N=132 The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers
Healthy Volunteers
Primary: The Comparison of BTDS to Placebo Transdermal System (TDS): the Average Difference From Baseline Using QT Corrected From Within-subject Data (QTci) on Day 13 — 4.20…
Phase 1 N=48 Phase I Study of OPC-61815
Congestive Heart Failure
Primary: Time-matched Difference Between the OPC-61815/Moxifloxacin and Placebo Data in Change From Baseline for QTcF in 12-lead Holter Electrocardiogram (ECG) — 0.9; 0.0; 9.9…
Phase 1 N=32 A Study to Evaluate the Effects of NST-4016 on QT/Corrected QT (QTc) Interval
Dyslipidemias
Primary: Change From Baseline in Fridericia's Correction for QT Interval (QTcF) — -4.6; 11.5; -6.0; -6.1 msec
Phase 1 N=57 A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
Healthy
Primary: Placebo-corrected Change From Baseline For QTcF (ΔΔQTcF) for ALXN1840 Using The By-time Point Analysis — -0.21; -0.31; 0.07; -0.64 ms
Phase 4 N=77 Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
Healthy
Primary: Setmelanotide Concentration-related Placebo-corrected Change From Baseline (CHFB) in Fridericia's Correction (QTcF) at Day 10 — 1.9; -1.5; -3.6; -3.5 milliseconds (msec)
Phase 1 N=48 Staccato Loxapine Thorough QT/QTc Study
Thorough QT/QTc Study
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 5.418 mseconds
Phase 1 N=54 To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
Solid Tumours
Primary: Change From Baseline in QTcF — 2.0; -4.1; -4.2 msec
Phase 1 N=27 A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects
Healthy Adult Subjects
Primary: Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186 — -0.5; 0.5 ms
Phase 1 N=107 A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
Schizophrenia
Primary: Change From Baseline in QT Interval Corrected for Heart Rate (QTc) Following MK-8189 Treatment — 4.31; -1.38; -0.61; -1.13 ΔQTcF (msec)